QLT

Contact
qltinc.com
+16047077000

QLT Inc.

887 Great Northern Way
V5T 4T5 Vancouver
Canada
+16047077000
qltinc.com
Contact
Profile News
Contact

About QLT

QLT is a biotechnology company dedicated to the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. We are focused on developing our synthetic retinoid program for the treatment of certain inherited retinal diseases.

QLT's head office is based in Vancouver, Canada and the company is publicly traded on NASDAQ (symbol: QLTI) and the Toronto Stock Exchange (symbol: QLT).

Read more about QLT
Facts about QLT
  • Focus : Manufacturer
  • Industry : Pharma

News about QLT

QLT

01-Apr-2008 | research and development

QLT initiates phase II study of punctal plug drug delivery system for glaucoma & ocular hypertension

QLT Inc. announced the initiation of patient recruitment into its "CORE" study, a phase II trial being conducted by QLT's wholly-owned subsidiary, QLT Plug ...

Read news
QLT

03-Sep-2007 | research and development

Eligard six-month formulation successfully completes European approval procedure

QLT USA, Inc., a subsidiary of QLT Inc., announced that the European approval procedure for the Eligard(R) 45 mg six-month formulation was successfully ...

Read news
QLT

09-Nov-2006 | research and development

QLT announces positive findings from Phase IV G6PD deficiency study for Aczone(TM) in acne

QLT Inc. announced positive results of a Phase IV clinical trial of Aczone(TM) in more than 50 patients with G6PD deficiency that was performed to meet a ...

Read news
QLT

08-Mar-2006 | research and development

QLT Updates on the U.S. Eligard Patent Litigation

Temporary Suspension of Eligard Sales in the U.S. by Sanofi-Synthelabo

Read news
Show more news about QLT

Here you will find QLT Inc.